Efficacy and outcome measures The 8 studies assessed the efficacy of GLP-1 in managing GDM, focusing on glycemic control, insulin sensitivity, and type 2 diabetes prevention
Corresponding data for heart failure were SGLT2is 0.49 (0.42, 0.58), GLP-1RAs 0.82 (0.710.95), and with combined therapy 0.43 (0.280.64)
In late 2025, orforglipron received a Commissioners National Priority Voucher, enabling an accelerated FDA review
Factor's free dietitian session is a genuine differentiator for patients working through GLP-1 nutritional changes for the first time, despite the higher cost and required subscription
For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isnt always straightforward, as it may not be clear what dose a patient on a compounded product had been taking